Shield HealthCare has sold a majority interest to Henry Schein
Shield Healthcare has sold a majority ownership position to Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners.
Founded in 1957 and headquartered in Valencia, California, Shield is one of the largest independent value-added distributors of essential medical supplies for patients and caregivers managing care in the home. The company’s diversified product catalog includes durable and consumable medical products for a wide range of patient diagnoses, including incontinence, enteral nutrition, ostomy, urology and advanced wound care. Shield operates across a nationwide footprint to provide superior solutions centered around improving patient outcomes and providing exceptional customer service and patient satisfaction.
Henry Schein is a solutions company for healthcare professionals powered by a network of people and technology. With approximately 24,000 members worldwide, the company’s network of trusted advisors provides over one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its business, clinical, technology and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics as well as other alternate care sites.
Oaklins Intrepid in Los Angeles acted as the exclusive sell-side advisor in this transaction.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Kyle Berkman
Oaklins Intrepid
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more